Edmund Chiong, - and Declan G. Murphy, - and Nicholas C. Buchan, - and Melvin L. K. Chua, - and Lukman Hakim, Lukman and Agus Rizal Hamid, - and Sung K. Hong, - and Ravi Kanesvaran, - and Makarand Khochikar, - and Jason Letran, - and Bannakij Lojanapiwat, - and Rohan Malek, - and Anthony C F Ng, - and Nguyễn Tuấn Vinh, - and See-Tong Pang, - and Darren M C Poon, - and Teng Aik Ong, - and Marniza Saad, - and Kathryn Schubach, - and Ryoichi Shiroki, - and Levent Türkeri, - and Scott Williams, - and Alvin Wong, - and Dingwei Ye, - Managing advanced prostate cancer in the Asia Pacific region: "Real-world" application of Advanced Prostate Cancer Consensus Conference 2019 statements. Asia-Pacific Journal of Clinical Oncology, 18 (6). ISSN 1743-7555; E-ISSN : 1743-7563

	Text (Artikel) 13. Managing advanced prostate.pdf Download (2MB)
	Text (Kualitas Karil & Kesesuaian Bidang Ilmu) 13.pdf Download (844kB)
	Text (Turnitin) 13. Managing advanced.pdf Download (2MB)

Abstract

Abstract Aim The second Asia-Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2020) gathered insights into the real-world application in the Asia-Pacific (APAC) region of consensus statements from the 3rd Advanced Prostate Cancer Consensus Conference (APCCC 2019). Methods The 4-h our virtual meeting in October 2020 brought together 26 experts from 14 APAC countries to discuss APCCC 2019 recommendations. Presentations were prerecorded and viewed prior to the meeting. A postmeeting survey gathered views on current practice. Results The meeting and survey highlighted several developments since APAC APCCC 2018. Increased access and use in the region of PSMA PET/CT imaging is providing additional diagnostic and staging information for advanced prostate cancer and influencing local and systemic therapy choices. Awareness of oligometastatic disease, although not clearly defined, is increasing. Novel androgen receptor pathway antagonists are expanding treatment options. Cost and access to contemporary treatments and technologies continue to be a significant factor influencing therapeutic decisions in the region. With treatment options increasing, multidisciplinary treatment planning, shared decision making, and informed choice remain critical. A discussion on the COVID-19 pandemic highlighted challenges for diagnosis, treatment, and clinical trials and new service delivery models that will continue beyond the pandemic. Conclusion APAC-specific prostate cancer research and data are important to ensure that treatment guidelines and recommendations reflect local populations and resources. Facilitated approaches to collaboration across the region such as that achieved through APAC APCCC meetings continue to be a valuable mechanism to ensure the relevance of consensus guidelines within the region.

Actions (login required)

View Item